Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2004-07-02
2009-06-30
Saidha, Tekchand (Department: 1652)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07553931
ABSTRACT:
The invention provides isolated polypeptides having complement-modulating activity. Specifically, the invention resides in the provision of isolated polypeptides having complement-depleting properties, i.e. that effect an efficient consumption of complement in human serum. The current invention thus provides human C3-derivatives that are capable of forming C3-convertases exerting an extended CVF, Bb-like half-life of up several hours, compared to 1.5 minutes of the naturally occurring C3-convertases, thus escaping the physiological degradation mechanisms.
REFERENCES:
Alper CA, Johnson AM, Birtch AG, and Moore FD (1969) Human C'3: evidence for the liver as the primary site of synthesis. Science, 163: 286-88.
Ames RS, Tometta MA, Jones CS, Tsui P. (1994) Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library. J. Immunol., 152(9):4572-81.
Ames RS, Tometta MA, Jones CS, Tsui P. (1994) Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library. J. Immunol., 153(2):910 (Erratum).
Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C., Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, and Kumar C. (1996) Molecular cloning and characterization of the human fanaphylatoxin C3a receptor. J. Biol. Chem, 271: 20231-34.
Andersson, J. Ekdahl, NK and Nilsson, B. (2003) Complement Activation on a Model Biomaterial Surface-Binding of C3B Via the Alternative Pathway Amplification Loop to Plasma Proteins Absorbed to the Surface, Immunoglogy, 40 (Abstract).
Bach FH, Robson SC, Winkler H, Ferran C, Stuhlmeier KM, Wrighton CJ, and Hancock WW. (1995) Barriers to xenotransplantation. Nat. Med., 1: 869-73.
Baldwin WM, 3rd, Pruitt SK, Brauer RB, Daha MR, and Sanfilippo F. (1995) Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation, 59: 797-808.
Ballow M and Cochrane CG. (1969) Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes to one of them J. Immunol., 103: 944-952.
Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, and Abramson S. (1986) Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during Exacerbations of disease. Arthritis. Rheum., 29: 1085-89.
Biesecker G, Dihel L, Enney K and Bendele RA. (1999) Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology, 42: 219-30.
Bohnsack JF and Cooper NR. (1988) CR2 ligands modulate human B cell activation. J. Immunol., 141: 2569-76.
Burger R. Zilow G, Bader A, Friedlein A, and Naser W. (1988) The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinat with diagnostic potential. J. Immunol., 141: 553-58.
Busch K, Piehler J, and Fromm H. (2000) Plant succinic semialdehyde dehydrogenase: dissection of nucleotide binding by surface plasmon resonance and fluorescence spectroscopy. Biochemistry, 39: 10110-10117.
Buyon JP, Tamerius J, Ordorica S, Young B, and Abramson SB. (1992) Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum., 35: 55-61.
Cheung AK, Parker CJ, and Hohnholt M. (1994) Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int., 46: 1680-87.
Christiansen D, Milland J, Thorley BR, McKenzie IF, and Loveland BE. (1996) A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro. Eur. J. Immunol., 26: 578-85.
Chrupcala M, Pomer S, Waldherr R, Staehler G, and Kirschfink M. (1996) Effect of complement modulation with the soluble complement receptor sCR1 on survival and function of kidney xenotransplant. An experimental study with a new guinea pig to rate transplant model. Urologe A., 35: 478-84.
Cochrane CG, Muller-Eberhard HJ, and Aikin BS. (1970) Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol., 105: 55-69.
Cooper PD. (1985) Complement and cancer: activation of the alternative pathway as a theoretical base for immunotherapy. Adv. Immun. Cancer Ther., 1: 125-66.
Cooper PD. and Sim RB. (1984) Substances that can trigger activation of the alternative pathway of complment have anti-melanoma activity in mice. Int. J. Cancer, 33: 683-87.
Couser WG, Baker PJ, and Adler S. (1985) Complement and the direct mediation of immune glomerular injury: a new perspective. Kidney Int., 28: 879-90.
Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, and Rudolph AR. (1995) The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J. Am. Soc. Nephrol., 5: 1888-94.
Craddock PR, Fehr J, Dalmasso AP, Brighan KL, and Jacob HS. (1977) Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J. Clin. Invest., 59: 879-88.
Dalmasso, A. P. (1997) Role of complement in xenografts redction, in Xenotransplantation: The Transplantation of Organs and Tissues Between Species, vol. 2nd ed (Cooper DK, Kemp E, Platt JL, and White DJ., eds), pp. 38-60. Springer, Berlin.
Daoudaki ME, Becherer JD, and Lambris JD. (1988) A 34 amino acid peptide of the third component of complement mediates properdin binding. J. Immunol., 140: 1577-80.
Davies A. (1996) Policing the membrane: cell surface proteins which regulate complement. Res. Immunol., 147: 82-87.
Davis AE. 3rd, and Harrison RA. (1982) Structural characterization of factor I mediated cleavage of the third component of complement. Biochemistry, 21: 5745-49.
DeBruijn MHL and Fey GH. (1985) Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. USA, 708-12.
Dolmer K and Sottrup-Jensen L. (1993) Disulfide bridges in human complement component C3b. FEBS Lett., 315: 85-90.
Eldering E, Huijbregts CC, Nuijens JH, Verhoeven AJ, and Hack CE. (1993) Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. J. Clin. Invest., 91: 1035-43.
Elsner J, Oppermann M, Czech W, Dobos G, Schopf E, Norgauer J, and Kapp A. (1994) C3a activates reative oxygen radical species production and intracellular calcium transients in human eosinophils. Eur. J. Immunol., 24: 518-22.
Eppinger MJ, Deeb GM, Bolling SF, and Ward PA. (1997) Mediators of ischemia-reperfusion injury of rat lung. Am. J. Pathol., 150: 1773-1784.
Fearon DT and Austen KF. (1975) Properdin: binding to C3b and stabilization of the C3bdependent C3-convertase. J. Exp. Med., 142: 856-863.
Fecke W, Farries TC, D'Cruz LG, Napper CM, and Harrison RA. (1998) Expression of factor I-resistant mutants of the human complement component C3 in heterologous systems.Xenotransplantation, 5: 29-34.
Fiane AE, Mollnes TE, Videm V, Hovig T, Hogasen K, Mellbye OJ, Spruce L, Moore WT, Sahu A, and Lambrs JD. (1999a) Prolongation of ex viveperfused pig xenograft survival by the complement inhibitor Compstatin. Transplant Proc., 31: 934-35.
Fiane AE, Mollnes TE, Videm V, Hovig T, Hogasen K, Mellbye OJ, Spruce L, Moore WT, Sahu A, and Lambris JD. (1999b) Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation, 6: 52-65.
Fishelson Z. (1991) Complement C3: a molecular mosaic-of binding sites. Mol. Immunol., 28: 545-52.
Fritzinger DC, Bredehorst R, and Vogel CW. (1994) Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. USA, 91: 12775-79.
Fritzinger DC, Petrella EC, Connelly MB, Bredehorst R, and Vogel CW. (1992) Primary structure of cobra complement component C3. J. Immunol., 149: 3554-62.
Fritzinger DC, Hew, B, Wehrhahn, D., and Vogel, CW (2003) Functional Characterization of Cobra Venom Factor/Cobra C3 Hybrid Proteins. Molecular Immunoglogy, 40 (Abstract).
Gonzalez-Rubio C, Ferreira-Cerdan A, Ponce IM, Arpa J, Fontan G, and Lopez-Trascasa M. (2001) Complement factor I defici
Bredehorst Reinhard
Kölln Johanna
Spillner Edzard
Ballard Spahr Andrews & Ingersoll LLP
PLS-Design GmbH
Saidha Tekchand
LandOfFree
Complement depletion using recombinant human C3-derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complement depletion using recombinant human C3-derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complement depletion using recombinant human C3-derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4069238